Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-39220675 vs Pseudoephedrine in Allergic Rhinitis
NCT00804687Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JNJ-39220675 in allergic rhinitis (AR), sponsored by Johnson & Johnson. Started Nov 2008; status: completed.
02
Drugs
JNJ-39220675
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT00804687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00804687.